Neurotez, based in Bridgewater Twp, NJ, is a biotechnology company dedicated to becoming a global leader in the development of innovative solutions for brain disorders. With a focus on central nervous system (CNS) drugs, their integrated platform spans from discovery to proof of concept clinical trials, aiming to deliver safe and efficacious treatments. Committed to excellence and responsible service to the public, Neurotez aims to transform the lives of individuals affected by conditions such as Alzheimer's disease and dementia.
Driven by a team of exceptional talent and capabilities, Neurotez utilizes biochemical, molecular cell biology, and in vivo models to screen, identify, and characterize suitable candidate drugs for Alzheimer's disease. Recognizing the intricate metabolic pathways underlying the pathology of Alzheimer's, the company leverages genetic, epidemiological, and in vitro studies to develop groundbreaking therapeutic approaches. With a vision to cure Alzheimer's disease and improve the understanding of aging-related cognitive decline, Neurotez is poised to make significant contributions in the field of neuroscience.
Generated from the website